DE2638716A1 - Antihypertensiva - Google Patents
AntihypertensivaInfo
- Publication number
- DE2638716A1 DE2638716A1 DE19762638716 DE2638716A DE2638716A1 DE 2638716 A1 DE2638716 A1 DE 2638716A1 DE 19762638716 DE19762638716 DE 19762638716 DE 2638716 A DE2638716 A DE 2638716A DE 2638716 A1 DE2638716 A1 DE 2638716A1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical preparation
- preparation according
- dosage
- hydrochloride
- hydrochlorothiazide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 26
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims description 21
- 229960001288 triamterene Drugs 0.000 claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 18
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 16
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 10
- 239000002876 beta blocker Substances 0.000 claims description 10
- 229960003712 propranolol Drugs 0.000 claims description 10
- 230000000894 saliuretic effect Effects 0.000 claims description 9
- 239000002934 diuretic Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 230000002077 kaliuretic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 description 20
- -1 heterocyclic radical Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 239000003826 tablet Substances 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 102100028255 Renin Human genes 0.000 description 7
- 108090000783 Renin Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229940030606 diuretics Drugs 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960004604 propranolol hydrochloride Drugs 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 229940122767 Potassium sparing diuretic Drugs 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229910001414 potassium ion Inorganic materials 0.000 description 3
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 3
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XZRKEDHJXXLVSK-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;6-phenylpteridine-2,4,7-triamine Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 XZRKEDHJXXLVSK-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960002155 chlorothiazide Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000011294 monotherapeutic Methods 0.000 description 2
- 230000036581 peripheral resistance Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010020955 Hypochloraemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- RRCPAXJDDNWJBI-UHFFFAOYSA-N alprenolol hydrochloride Chemical compound [H+].[Cl-].CC(C)NCC(O)COC1=CC=CC=C1CC=C RRCPAXJDDNWJBI-UHFFFAOYSA-N 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- WHLPIOPUASGRQN-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C WHLPIOPUASGRQN-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- VKMGSWIFEHZQRS-UHFFFAOYSA-N dichloroisoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(Cl)C(Cl)=C1 VKMGSWIFEHZQRS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 1
- 229960002877 dihydralazine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229940080360 rauwolfia alkaloid Drugs 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762660861 DE2660861C2 (enExample) | 1976-08-27 | 1976-08-27 | |
| DE19762638716 DE2638716A1 (de) | 1976-08-27 | 1976-08-27 | Antihypertensiva |
| FR7725671A FR2362636A1 (fr) | 1976-08-27 | 1977-08-23 | Composition therapeutique pour le traitement des etats d'hypertension |
| GB35524/77A GB1584089A (en) | 1976-08-27 | 1977-08-24 | Antihypertensive pharmaceutical compositions |
| JP10249477A JPS5350340A (en) | 1976-08-27 | 1977-08-26 | Medicine having blood pressure depressing effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762638716 DE2638716A1 (de) | 1976-08-27 | 1976-08-27 | Antihypertensiva |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2638716A1 true DE2638716A1 (de) | 1978-03-02 |
Family
ID=5986558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762638716 Ceased DE2638716A1 (de) | 1976-08-27 | 1976-08-27 | Antihypertensiva |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS5350340A (enExample) |
| DE (1) | DE2638716A1 (enExample) |
| FR (1) | FR2362636A1 (enExample) |
| GB (1) | GB1584089A (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043548A1 (de) * | 1980-07-04 | 1982-01-13 | Hoechst Aktiengesellschaft | Salz aus Furosemid oder Piretanid als Säurekomponente und Penbutolol als Basenkomponente sowie Arzneimittel, das beide Komponenten enthält |
| EP0039388A3 (de) * | 1980-05-02 | 1982-10-06 | Röhm Pharma GmbH | Diagnostisches Verfahren zur Bestimmung der Leberfunktion |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0022330B1 (en) * | 1979-07-10 | 1983-12-21 | Smithkline Beckman Corporation | Synergistic antihypertensive compositions |
| EP0081006B1 (en) * | 1981-12-08 | 1985-09-25 | Smithkline Beckman Corporation | Pharmaceutical compositions comprising 7,8-dihydroxy-1(hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine derivatives and a beta-adrenergic blocking compound |
| US4898729A (en) * | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| HU196125B (en) * | 1985-02-05 | 1988-10-28 | Sandoz Ag | Process for producing pharmaceutical comprising 3-(aminopropoxy)-indole derivatives combined with diuretic |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1417864A (en) | 1971-12-10 | 1975-12-17 | Sandoz Ltd | Antihyertensive compositions |
-
1976
- 1976-08-27 DE DE19762638716 patent/DE2638716A1/de not_active Ceased
-
1977
- 1977-08-23 FR FR7725671A patent/FR2362636A1/fr active Granted
- 1977-08-24 GB GB35524/77A patent/GB1584089A/en not_active Expired
- 1977-08-26 JP JP10249477A patent/JPS5350340A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1417864A (en) | 1971-12-10 | 1975-12-17 | Sandoz Ltd | Antihyertensive compositions |
Non-Patent Citations (1)
| Title |
|---|
| H. Hornbostel et al., Innere Medizin in Praxis und Klinik, Bd.II, S.6-15 bis 6-19 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0039388A3 (de) * | 1980-05-02 | 1982-10-06 | Röhm Pharma GmbH | Diagnostisches Verfahren zur Bestimmung der Leberfunktion |
| EP0043548A1 (de) * | 1980-07-04 | 1982-01-13 | Hoechst Aktiengesellschaft | Salz aus Furosemid oder Piretanid als Säurekomponente und Penbutolol als Basenkomponente sowie Arzneimittel, das beide Komponenten enthält |
| US4564625A (en) * | 1980-07-04 | 1986-01-14 | Hoechst Aktiengesellschaft | Binary compositions of penbutolol and furosemide or piretanide |
Also Published As
| Publication number | Publication date |
|---|---|
| GB1584089A (en) | 1981-02-04 |
| FR2362636B1 (enExample) | 1980-12-05 |
| JPS5350340A (en) | 1978-05-08 |
| FR2362636A1 (fr) | 1978-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2856393C2 (de) | Arzneimittel zur Behandlung von Morbus Parkinson | |
| US4757072A (en) | Carcinostatic agent | |
| EP0864327B1 (de) | Verwendung von Pyrimidinderivaten zur Herstellung eines Arzneimittels zur Prävention von Krebs | |
| DE2523998A1 (de) | Pharmazeutische zubereitung fuer die behandlung der schizophrenie | |
| EP0752246A2 (de) | Kappa-Opiate für entzündliche Darmerkrankungen | |
| DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| DE2638716A1 (de) | Antihypertensiva | |
| DE69330638T2 (de) | Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem | |
| DE3874900T2 (de) | Wirkstoff mit die nierenfunktion verbesserndem und diuretischem effekt und verwendung eines darin enthaltenen benzothiazepin-derivates. | |
| DE3739779A1 (de) | Pharmazeutische praeparate | |
| DE2658500C2 (de) | Pharmazeutische Präparate mit kardioprotektiver Wirkung | |
| DE2660861C2 (enExample) | ||
| DE3141970C2 (enExample) | ||
| EP1137438A1 (de) | Zubereitung mit verbesserter therapeutischer breite, enthaltend nukleotidsyntheseinhibitoren | |
| DE69528068T2 (de) | Conagenine zur prävention und behandlung von diarrhöe | |
| DE3419425C2 (enExample) | ||
| DE2437272C3 (de) | 6-Trifluormethyl-2H-1,2,4-benzothiadiazin-1,1-dioxyde und sie enthaltende Arzneimittelzubereitungen | |
| DE3904795C2 (de) | Pharmazeutisches Präparat und dessen Verwendung | |
| DE3213579C2 (enExample) | ||
| EP0508511B1 (de) | Erzeugnisse, enthaltend Verapamil und Trandolapril | |
| EP1307195A2 (de) | Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten | |
| EP1919483B1 (de) | Kombinationspräparat aus einem thiaziddiuretikum und einem schleifendiuretikum | |
| DE10138538C2 (de) | Tumorhemmende Lanthanverbindungen | |
| DE3532036A1 (de) | Pharmazeutische zubereitung zur behandlung des bluthochdrucks | |
| DE3908232C2 (de) | Verwendung von Verapamil zur Behandlung der Schlaf-Apnoe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 2660861 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 2660861 |
|
| 8131 | Rejection | ||
| AH | Division in |
Ref country code: DE Ref document number: 2660861 Format of ref document f/p: P |